Johnson & Johnson
JNJEquityAI Summary
Updated 8h ago
Johnson & Johnson (JNJ) is showing an interesting divergence
Johnson & Johnson (JNJ) is showing an interesting divergence. Price has pulled back — extension indicators are in the lower portion of their historical range — but buying pressure is holding up. Flow indicators remain above average despite the price weakness. For reference: Flow Score 43/100, Trend & Momentum Score 66/100.
Market Positioning
What's Happening
J&J posted solid first-quarter results and raised 2026 targets
On 2026-04-14, Johnson & Johnson reported first-quarter 2026 EPS of $2.70, topping the $2.67 consensus cited by Public.com. The more important signal was that management kept its full-year 2026 framing constructive after a quarter that showed the company can still grow while absorbing a complex mix of patent cliffs, litigation noise, and portfolio shifts.
The Bigger Picture
Macro context will be updated shortly
Upcoming Catalysts
Updated 48d agoJohnson & Johnson has scheduled its second-quarter 2026 earnings call for July 15, 2026. Investors will focus on whether the company can keep full-year guidance on track after the April reset and whether ex-Stelara momentum is still broad-based.
The July 15 report will be the next hard checkpoint on revenue mix, margins, and EPS execution. The key issue is whether the April view — $100.2 billion midpoint sales guidance and $11.30-$11.50 adjusted operational EPS — remains realistic after another quarter of commercial and pipeline execution.
Over the next 90 days, any FDA or other regulatory updates tied to Johnson & Johnson’s Innovative Medicine or MedTech portfolio could move sentiment quickly. The market will be watching for evidence that the company can convert its broad R&D spend into incremental approvals and labeling expansions.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Johnson & Johnson (JNJ): extension is below average (28th percentile), momentum is below average (28th percentile), flow is neutral (52nd percentile), volatility is above average (82nd percentile). This is an interesting combination. Extension and momentum are both at historically low levels — price is compressed and has lost upward energy — while flow indicators remain steady. This pattern, where price has weakened but buying pressure is holding, has historically been associated with periods that resolved to the upside more often than not. That said, it is not a prediction — it is context.
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Johnson & Johnson (JNJ) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required